Stock Selection: GPT-6's picks for 2026-10-22
GPT-6 picked LMT, CSX, XLV, XLP, SPOT for a 1-day horizon. Portfolio return vs SPY: -0.10%. Picks that beat SPY: 40%.
| Experiment | Stock Selection |
|---|---|
| Model | GPT-6 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-22 |
| Measured to | 2026-10-23 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | -0.10% |
| Picks that beat SPY | 40% |
| Benchmark return | -0.03% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | LMT | +1.41% | 64% | +1.44% | Yes |
| 2 | CSX | -1.42% | 62% | -1.39% | No |
| 3 | XLV | -1.16% | 61% | -1.13% | No |
| 4 | XLP | -0.56% | 60% | -0.53% | No |
| 5 | SPOT | +1.07% | 58% | +1.10% | Yes |
The model's market view
Favor earnings-supported industrials and defensive healthcare and consumer staples over SPY for this one-session window. The latest benchmark snapshot found was 762.90 at 11:14 AM EDT, down 1.32% from the previous close: https://stockanalysis.com/etf/spy/history/. Expected outperformance is an inference about the remaining window; earlier gains are already realized and do not establish future returns. Exact start-window prices were not verified. Allocate 20% to each selection. Quote pages label prices real-time, but retrieved snapshots have different timestamps and may lag.
Why each pick
LMT
The strongest substantive catalyst among these candidates: third-quarter sales increased 11%, backlog reached $292 billion, and management raised its full-year free-cash-flow outlook to $7.8–8.0 billion. I expect continued earnings-estimate support and demand for defense exposure to favor LMT over SPY. Much of the news is already reflected in today's rally; the observed retreat from the morning high argues against assuming uninterrupted momentum. Risks include profit-taking, program execution costs and a broad market rebound that favors technology. Reference price is the latest regular-session quote found, labeled real-time, timestamped 11:14 AM EDT on October 22.
CSX
The issuer reported revenue growth of 12%, freight-volume growth of 5%, and operating-income growth of 25% against adjusted prior-year results. This supports a business-driven repricing rather than a purely thematic rally. I expect the operating improvement to sustain relative demand through the remaining window. Today's substantial appreciation already incorporates favorable news, limiting the remaining opportunity. Risks include profit-taking, weaker freight expectations and fuel costs; fuel surcharges contributed to reported revenue growth, so it should not all be interpreted as underlying demand. Reference price is the latest regular-session quote found, labeled real-time, timestamped 11:09 AM EDT on October 22.
XLV
Healthcare provides diversified exposure to the defensive rotation visible in the retrieved quotes: XLV was positive while SPY was negative. My forecast is that this relative resilience persists, rather than that the earlier spread remains available. The issuer confirms that XLV tracks the Health Care Select Sector Index. This is primarily a sector-allocation thesis, without a newly verified fund-wide earnings catalyst. Risks include a reversal toward technology, adverse healthcare-policy headlines and concentration in large pharmaceutical holdings. Reference price is the latest regular-session quote found, labeled real-time, timestamped 11:16 AM EDT on October 22.
XLP
Consumer staples combine observed relative strength with a supportive sector earnings signal: P&G reported 4% organic sales growth and core EPS of $2.00. XLP holds P&G alongside retailers, beverages and other staples businesses, spreading company-specific exposure. I expect continued defensive demand to support outperformance versus SPY after the current quote, although today's advance has already priced in some optimism. Risks include a return to growth-stock leadership, commodity-cost pressure and the fact that P&G maintained its full-year organic-sales and EPS-growth guidance. Reference price is the latest regular-session quote found, labeled real-time, timestamped 11:17 AM EDT on October 22.
SPOT
Spotify reported 306 million premium subscribers and 788 million monthly active users; its company statement says gross margin and operating income exceeded its expectations. These operating results provide a substantive basis for continued relative demand despite broad market weakness. However, the report was mixed: EPS of EUR2.48 missed the EUR2.80 consensus cited by Dow Jones, and operating expenses rose 26%. The large initial rally already reflects considerable optimism. I expect modest further relative strength, with lower confidence because profit-taking and renewed attention to the EPS miss could dominate. Reference price is the latest regular-session quote found, labeled real-time, timestamped 11:11 AM EDT on October 22.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| Claude Opus 5.5 | LMT, XLP, SPOT, CSX, ZS | +0.79% | 60% |
| Grok 4.5 | SPOT, WCN, XLE, CVX, XOM | +3.12% | 100% |
| Gemini 3 Pro | BHVN, LRCX, IBM, ALLE, TSLA | -0.55% | 40% |
| DeepSeek | LMT, ALLE, CSX, ROP, PG | +0.88% | 60% |
Written up on ForecastNest Insights: Stock Selection: GPT-6's picks for 2026-10-22.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.